期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 61, 期 1, 页码 90-104出版社
WILEY
DOI: 10.1002/jcph.1703
关键词
sarilumab; tocilizumab; pharmacokinetics; interleukin-6; neutrophils; C-reactive protein
资金
- Sanofi Genzyme
- Regeneron Pharmaceuticals, Inc.
In this study, pharmacokinetics, pharmacodynamics, and PK/PD relationships of two different drugs for rheumatoid arthritis patients were evaluated. The onset of efficacy and safety profiles were similar for both drugs, despite differences in pharmacokinetics. This suggests that subcutaneous sarilumab and intravenous tocilizumab have comparable effects in reducing inflammation and maintaining white blood cell count in patients with inadequate responses to methotrexate.
We assessed pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of interleukin-6 (IL-6), soluble IL-6 receptor, and C-reactive protein (CRP) in serum, and absolute neutrophil count (ANC) in blood following single doses of subcutaneous sarilumab versus intravenous tocilizumab (NCT02097524) from patients with rheumatoid arthritis (RA) who are inadequate responders to methotrexate (MTX) and on a stable dose of MTX. Patients with RA randomized (1:1:1:1) to single-dose sarilumab (150 or 200 mg subcutaneously) or tocilizumab (4 or 8 mg/kg intravenously) were included (n = 101), and PK, PD, and PK/PD relationships and safety were assessed over 6 weeks postdose. PK profiles for both drugs are described by parallel linear and nonlinear target-mediated clearance pathways. PD markers showed similar onset of effect during the first week postdose, regardless of dose or route of administration. CRP and ANC decreased, with median postdose nadirs at 7-15 days for CRP and 3-5 days for ANC. Both drugs at low and high doses achieved the same nadir for ANC and a similar return toward baseline within 2 weeks postdose, suggesting a saturation of effect. Safety profiles of sarilumab and tocilizumab were generally similar. In conclusion, despite differences in PK, the onset of the decrease in CRP (efficacy) and ANC (safety) after a single dose were similar for subcutaneous sarilumab and intravenous tocilizumab. PD effects and safety were consistent with previous studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据